Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Brandon Couillard maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $4.5 to $5.5.
Wells Fargo analyst Brandon Couillard maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $4.5 to $5.5.